|
|||||
|
|
| 顺铂联合长春瑞滨同步放化疗治疗局部晚期非小细胞肺癌的长期疗效 | |
| 引用本文： | 游震宇,汪小浪,郭宇玲,陈少卿,李克,陈丽芳. 顺铂联合长春瑞滨同步放化疗治疗局部晚期非小细胞肺癌的长期疗效[J]. 矿产勘查, 2013, 0(10): 47-49,52 |
| 作者姓名： | 游震宇 汪小浪 郭宇玲 陈少卿 李克 陈丽芳 |
| 作者单位： | 南昌大学第一附属医院肿瘤科,南昌330006 |
| 摘 要： | 目的 探讨顺铂联合长春瑞滨（NP方案）同步放疗治疗局部晚期非小细胞肺癌的长期疗效及毒副作用.方法 随访57例NP方案同步放化疗病例.NP方案为长春瑞滨25 mg·m-2,第1、8天;顺铂25 mg·m-2第1-3天,21 d为1个周期.放疗采用适形放疗,总剂量为60～70 Gy,6～7周完成放疗.同步放化疗于放疗第1天开始,放疗期间共行2个周期化疗,放疗结束后继续接受2个周期化疗.观察治疗后1、3、5年的无复发生存期（PFS）和总生存期（OS）及晚期毒副作用（肺毒性、食管毒性）.结果 同步放化疗后客观缓解率为80.7%,1、3、5年无进展生存率为51.8%、22.2%、16.7%,相应的总生存率为80.5%、37.3%和21.0%;中位无进展生存时间、总生存时间分别为12.8和29.9个月.1级、2级、3级晚期肺毒副作用分别为14例、12例、5例,无4级和5级晚期肺毒副作用,26例（45.6%）未见晚期毒副作用.晚期食管毒副作用3例,均为1级反应,无2级以上食管晚期毒副作用.结论 顺铂联合长春瑞滨同步放化疗治疗局部晚期非小细胞肺癌的长期疗效显著,且毒副作用可耐受. |
| 关 键 词： | 非小细胞肺癌 同步放化疗 NP方案 顺铂 长春瑞滨 远期疗效 |
Long-term Efficacy of Concurrent Radiochemotherapy with Cisplatin Plus Vinorelbine in Locally Advanced Non-small Cell Lung Cancer |
|
| YOU Zhen-yu,WANG Xiao-lang,GUO Yu-ling,CHEN Shao-qing,LI Ke,CHEN Li-fang. Long-term Efficacy of Concurrent Radiochemotherapy with Cisplatin Plus Vinorelbine in Locally Advanced Non-small Cell Lung Cancer[J]. Mineral Exploration, 2013, 0(10): 47-49,52 | |
| Authors: | YOU Zhen-yu WANG Xiao-lang GUO Yu-ling CHEN Shao-qing LI Ke CHEN Li-fang |
| Affiliation: | (Department of Oncology ,the First Affiliated Hospital of Nanchang University, Nanchang 330006, China) |
| Abstract: | Objective To evaluate the long-term effect and side effect of concurrent radioche- motherapy with cispatin plus vinorelbine （NP regimen） on locally advanced non-small cell lung cancer （NSCLC）. Methods Fifty-seven patients with locally advanced NSCLC who underwent concurrent radiochemotherapy with NP regimen were followed up. All patients were given cispla- tin （25 mg~ m-2） on day 1-3 and vinorelbine （[25 mg m-2） on day 1 and 8 every 3 weeks. Con- formal radiotherapy （CRT） was performed on the first day of radiotherapy. The total dose of 60- 70 Gy was completed within 6-7 weeks. Patients received 2 cycles of chemotherapy during and af- ter radiotherapy, respectively. The 1-, 3-and 5-year progression-free rates, overall survival time and late side effects （pulmonary or esophageal toxicity） were observed. Results The objective re- sponse rate was 80. 7% after concurrent radiochemotherapy. The 1-,3-and 5-year progression-free rates were 51,8 %, 22.2 % and 16.7 %, respectively. The corresponding total survival rates were 80.5%,37.3% and 21.0%,respectively. The median progression-free survival time and overall survival time were 12. 8 months and 29. 9 months, respectively. Among the 57 patients, 26 （45.6%） showed no late pulmonary toxicities. Grade 1,2 and 3 late pulmonary toxicities were ob- served in 14,12 and 5 patients, respectively. No grade 4 and 5 pulmonary toxicities were found. Grade 1 late esophageal toxicities occurred in 3 patients. No grade 2 or more late esophageal toxic- ities were found. Conclusion Concurrent radiochemotherapy with cispatin plus vinorelbine is ef- fective in long-term treatment of locally advanced NSCLC,and the toxicities are tolerable. |
| Keywords: | non-small cell lung cancer concurrent chemoradiotherapy NP regimen cisplatin vinorelbine long-term efficacy |
| 本文献已被 维普 等数据库收录！ | |